Development of a triplex endpoint PCR assay for the detection of SARS-CoV-2: insights on cost-efficiency and method design.

Pub Date : 2024-10-29 DOI:10.1159/000542308
Camelia Vintilă, Razvan Lucian Coșeriu, Anca Delia Mare, Cristina Nicoleta Ciurea, Radu Togănel, Anastasia Simion, Anca Cighir, Adrian Man
{"title":"Development of a triplex endpoint PCR assay for the detection of SARS-CoV-2: insights on cost-efficiency and method design.","authors":"Camelia Vintilă, Razvan Lucian Coșeriu, Anca Delia Mare, Cristina Nicoleta Ciurea, Radu Togănel, Anastasia Simion, Anca Cighir, Adrian Man","doi":"10.1159/000542308","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Lower respiratory tract infections, including COVID-19, have a substantial global impact, making the development of diagnostic tests crucial. The study aimed to develop a new, accurate, fast, and cost-effective PCR-based detection method for SARS-CoV-2, applicable in limited settings and capable of detecting all current variants and potential future pathogens.</p><p><strong>Methods: </strong>The study was conducted between 2020 and 2022 at the molecular biology department of Mures County Clinical Hospital, Romania. Initially, pharyngeal and nasal secretions were collected and processed using the real-time qRT-PCR method for routine COVID-19 diagnosis. Ninety-two samples were randomly selected to develop the assay, including samples from different infection periods and negative controls. Complementary DNA (cDNA) was prepared from the selected samples, and the presence and integrity of the extracted RNA were evaluated by amplifying the GAPDH housekeeping gene. Primers for three specific viral genes (N, ORF1ab, and S) were designed, and their efficiency was evaluated using endpoint PCR and sequencing. Finally, the method was optimized and implemented as a one-step triplex PCR assay for routine diagnostic use.</p><p><strong>Results: </strong>The molecular laboratory at the Mures County Clinical Hospital (MCCH) analyzed a total of 41,818 samples between June 2020 and December 2022. Among these samples, 26.15% tested positive for SARS-CoV-2, while 70.9% were negative and 2.95% were inconclusive or invalid. Three peaks of positive tests were observed in November 2020, April 2021, and February 2022. The study selected 92 preserved RNA samples for triplex-PCR assay development, validating the primers' specificity and confirming the quality of the nucleic acids. The comparative analysis showed the efficiency and accuracy of the endpoint reverse-transcription triplex-PCR method (RT-PCR), indicating its potential as a cost-effective alternative to real-time reverse-transcription PCR (qRT-PCR) in low-income countries with limited infrastructure for COVID-19 testing.</p><p><strong>Conclusion: </strong>This method has the potential to facilitate large-scale diagnosis of SARS-CoV-2 infections, allowing for rapid and appropriate therapeutic management and ongoing monitoring of patients. Additionally, the method can be easily adapted for the detection of other pathogens.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1159/000542308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Lower respiratory tract infections, including COVID-19, have a substantial global impact, making the development of diagnostic tests crucial. The study aimed to develop a new, accurate, fast, and cost-effective PCR-based detection method for SARS-CoV-2, applicable in limited settings and capable of detecting all current variants and potential future pathogens.

Methods: The study was conducted between 2020 and 2022 at the molecular biology department of Mures County Clinical Hospital, Romania. Initially, pharyngeal and nasal secretions were collected and processed using the real-time qRT-PCR method for routine COVID-19 diagnosis. Ninety-two samples were randomly selected to develop the assay, including samples from different infection periods and negative controls. Complementary DNA (cDNA) was prepared from the selected samples, and the presence and integrity of the extracted RNA were evaluated by amplifying the GAPDH housekeeping gene. Primers for three specific viral genes (N, ORF1ab, and S) were designed, and their efficiency was evaluated using endpoint PCR and sequencing. Finally, the method was optimized and implemented as a one-step triplex PCR assay for routine diagnostic use.

Results: The molecular laboratory at the Mures County Clinical Hospital (MCCH) analyzed a total of 41,818 samples between June 2020 and December 2022. Among these samples, 26.15% tested positive for SARS-CoV-2, while 70.9% were negative and 2.95% were inconclusive or invalid. Three peaks of positive tests were observed in November 2020, April 2021, and February 2022. The study selected 92 preserved RNA samples for triplex-PCR assay development, validating the primers' specificity and confirming the quality of the nucleic acids. The comparative analysis showed the efficiency and accuracy of the endpoint reverse-transcription triplex-PCR method (RT-PCR), indicating its potential as a cost-effective alternative to real-time reverse-transcription PCR (qRT-PCR) in low-income countries with limited infrastructure for COVID-19 testing.

Conclusion: This method has the potential to facilitate large-scale diagnosis of SARS-CoV-2 infections, allowing for rapid and appropriate therapeutic management and ongoing monitoring of patients. Additionally, the method can be easily adapted for the detection of other pathogens.

分享
查看原文
开发用于检测 SARS-CoV-2 的三重终点 PCR 检测法:对成本效益和方法设计的见解。
导言:包括 COVID-19 在内的下呼吸道感染对全球影响巨大,因此开发诊断测试至关重要。本研究旨在开发一种基于 PCR 的 SARS-CoV-2 新型、准确、快速且经济高效的检测方法,该方法适用于有限的环境,并能检测当前的所有变种和未来潜在的病原体:这项研究于 2020 年至 2022 年期间在罗马尼亚 Mures 县临床医院分子生物学部进行。首先收集咽部和鼻腔分泌物,并使用实时 qRT-PCR 方法进行处理,以进行 COVID-19 的常规诊断。随机抽取了 92 份样本,包括不同感染期的样本和阴性对照,用于开发检测方法。从所选样本中制备互补 DNA(cDNA),并通过扩增 GAPDH 看家基因来评估提取的 RNA 的存在和完整性。设计了三个特定病毒基因(N、ORF1ab 和 S)的引物,并通过终点 PCR 和测序评估了它们的效率。最后,对该方法进行了优化,并将其作为常规诊断使用的一步三重 PCR 检测方法:穆雷县临床医院(MCCH)分子实验室在 2020 年 6 月至 2022 年 12 月期间共分析了 41818 份样本。在这些样本中,26.15%的样本检测出 SARS-CoV-2 阳性,70.9%的样本检测出阴性,2.95%的样本检测结果不确定或无效。在 2020 年 11 月、2021 年 4 月和 2022 年 2 月出现了三个阳性检测高峰。研究选取了 92 份保存的 RNA 样本进行三重 PCR 检测开发,验证了引物的特异性,并确认了核酸的质量。对比分析表明,终点反转录三重PCR方法(RT-PCR)的效率和准确性都很高,表明在基础设施有限的低收入国家,该方法有可能成为实时反转录PCR(qRT-PCR)的一种经济有效的替代方法,用于COVID-19检测:结论:这种方法有可能促进大规模诊断 SARS-CoV-2 感染,从而对患者进行快速、适当的治疗管理和持续监测。此外,该方法还可用于检测其他病原体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信